Anavex Life Sciences Corp (AVXL)

[kevli33]

One of Anavex's Scientific advisors (Harald Hampel) speaking at AAT 2018 in Italy March 15-18

http://aat-adpd.kenes.com/2018/scientific-program-(2)/meet-the-speakers#.WohepSMUXR0

This is Hampel bio from conference (Lots of Precision Medicine in bio)

Professor Harald Hampel, MD, PhD, MA, MSc AXA Research Fund & UPMC Excellence Chair Professor at Sorbonne Universities, Pierre and Marie Curie University (UPMC) Principal Investigator of the UPMC Clinical Research Group "Alzheimer Precision Medicine" Institute for Memory and Alzheimer's Disease (IM2A) Brain & Spine Institute (ICM) Department of Neurology Pitié-Salpétrière University Hospital 75013 Paris, France [e-mail] [e-mail] After a post-doctoral fellowship at the National Institute of Health (Bethesda, USA), he became full professor of psychiatry and founding director of the Alzheimer Memorial Center at Munich University before being appointed professor and chair of psychiatry at Trinity College, Dublin. In 2010, he was appointed as full professor & chair of psychiatry at the University of Frankfurt. In 2013 he was appointed as full professor and AXA Research Fund Chair on Alzheimer Disease at Pierre and Marie Curie University (UPMC). He is Scientific Director of the Institut for Memory and Alzheimer’s Disease, Department of Neurology, Pitié-Salpêtrière University Hospital in Paris, France. Since 2017 Chair and Principal Investigator of the UPMC Clinical Research Group on Alzheimer Precision Medicine (GRC No. 21) and of the Alzheimer Precision Medicine Initiative (APMI). He is also chairing the International Cholinergic System Working Group (CSWG) and is Senior Associate Editor of the journal of the Alzheimer Association, Alzheimer’s & Dementia. Dr. Hampel’s major research interests and contributions include the discovery and development of multimodal genetic/genomic, biochemical, neurodynamic and neuroimaging biomarkers of neurodegenerative diseases. This includes the validation of multimodal biomarker candidates in mono- and multi-site studies for progression, prediction, detection, diagnosis and classification of AD at different disease stages. His major objective is to transform traditional Neurology, Psychiatry and Neuroscience embracing Precision Medicine based on Complex Systems Theory using Systems Biology and Neurophysiology, Big Data Science and Biomarker-guided Integrative Disease Modeling (IDM) for improved detection, classification and biomarker-guided targeted therapy development in neurodegenerative diseases, such as Alzheimer's disease. Dr. Hampel published more than 700 peer-reviewed research papers and edited 8 books, won multiple awards for his research. He holds several large-scale national and international research grants and is principal investigator of numerous research programs and consortia.